Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at Roth Capital
Celldex Therapeutics Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by equities research analysts at Roth Capital in a research note issued on Thursday. They currently have a $7.00 price target on the biopharmaceutical company’s stock. Roth Capital’s target price would indicate a potential upside of 73.70% from the company’s current price.
Several other equities research analysts have also recently issued reports on CLDX. Jefferies Group lifted their target price on Celldex Therapeutics to $5.00 and gave the stock a “hold” rating in a report on Friday, August 5th. Wedbush reiterated a “neutral” rating and issued a $3.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 9th. Brean Capital started coverage on Celldex Therapeutics in a research report on Tuesday, October 4th. They issued a “buy” rating and a $16.00 price target for the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a research report on Monday, October 10th. Finally, Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 19th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $7.75.
Celldex Therapeutics (NASDAQ:CLDX) opened at 4.03 on Thursday. The company’s market cap is $405.20 million. Celldex Therapeutics has a 12 month low of $2.85 and a 12 month high of $18.62. The stock has a 50 day moving average price of $3.63 and a 200 day moving average price of $4.04.
Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. Celldex Therapeutics had a negative return on equity of 49.27% and a negative net margin of 1,923.41%. The firm had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $1.09 million. During the same period in the previous year, the firm posted ($0.32) earnings per share. The business’s revenue was up 115.5% compared to the same quarter last year. Analysts anticipate that Celldex Therapeutics will post ($1.34) earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in CLDX. State Street Corp raised its stake in shares of Celldex Therapeutics by 158.9% in the first quarter. State Street Corp now owns 8,561,225 shares of the biopharmaceutical company’s stock worth $32,362,000 after buying an additional 5,254,100 shares during the last quarter. Columbia Wanger Asset Management LLC raised its stake in shares of Celldex Therapeutics by 76.8% in the second quarter. Columbia Wanger Asset Management LLC now owns 5,261,934 shares of the biopharmaceutical company’s stock worth $23,100,000 after buying an additional 2,285,534 shares during the last quarter. A.R.T. Advisors LLC purchased a new stake in shares of Celldex Therapeutics during the first quarter worth about $3,446,000. Vanguard Group Inc. raised its stake in shares of Celldex Therapeutics by 7.3% in the second quarter. Vanguard Group Inc. now owns 7,263,339 shares of the biopharmaceutical company’s stock worth $31,886,000 after buying an additional 492,102 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Celldex Therapeutics by 94.9% in the first quarter. JPMorgan Chase & Co. now owns 690,128 shares of the biopharmaceutical company’s stock worth $2,608,000 after buying an additional 336,049 shares during the last quarter. Hedge funds and other institutional investors own 78.41% of the company’s stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.